Biblio
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022;9(5):e350-e360.
Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3(24):4326-4335.
. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. Br J Haematol. 2019.
Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm. Leuk Res Rep. 2023;20:100380.
. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022.
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases. Am J Hematol. 2021.
Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. Int J Hematol. 2023.
. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J. 2022;12(12):169.
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia. Lancet Haematol. 2022;9(5):e317-e318.
. . [Venetoclax-based salvage in multiple myeloma with (11;14) translocation after suboptimal response to first-line therapy]. Orv Hetil. 2023;164(23):894-899.
. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):57.
Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy. Eur J Haematol. 2023.
. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting. Exp Hematol Oncol. 2024;13(1):17.
Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia. Leuk Res. 2023;135:107407.
. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. Hematol Oncol Stem Cell Ther. 2023;16(4):346-350.
. Venetolax with Azacitidine Drains Fuel from AML Stem Cells. Cell Stem Cell. 2019;24(1):7-8.
. Venoarterial Extracorporeal Membrane Oxygenation After Autologous Stem Cell Transplantation With Pancytopenia: JACC Patient Care Pathways. J Am Coll Cardiol. 2023.
. Venom peptides in cancer therapy: An updated review on cellular and molecular aspects. Pharmacol Res. 2020:105327.
. Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: Did the Modified Seattle Criteria fit the characteristics of pediatric population?. Adv Clin Exp Med. 2020.
. Veno-occlusive disease of the lung after allogeneic haematopoietic stem-cell transplantation: An autopsy study. Pathol Res Pract. 2022;231:153799.
. Venous thromboembolism in heart transplantation: Should we consider genetic predisposition?. J Heart Lung Transplant. 2014.
. Venous thromboembolism in hematopoietic stem cell transplantation: A narrative review. Thromb Res. 2023;226:141-149.
. .